Real-World Evidence: Cannabinoid Therapy in Patients on Incretin (GLP-1 RA) Weight Management Protocols
Real-World Evidence: Cannabinoid Therapy in Patients on Incretin (GLP-1 RA) Weight Management Protocols
Emerging clinical observations evaluating cannabinoid co-therapy for GLP-1-induced nausea, visceral hypersensitivity, and gastric motility balance. Derived from longitudinal physician evaluations across 81,008 unique clinical cohorts and 130,447 structured follow-up encounters at CED Clinic, informed by Dr. Benjamin Caplan’s career oversight of 350,000+ patient evaluations.
Methodology & Observational Grounding
Unlike traditional pharmaceutical clinical trials that restrict inclusion criteria to single-diagnosis participants devoid of concurrent medications, the CED Clinic Real-World Evidence Registry captures the complex clinical reality of outpatient cannabinoid medicine. Patients in this cohort were systematically evaluated under board-certified physician supervision, with structured longitudinal tracking of symptom burden, medication de-escalation, adverse event incidence, and chemovar responsiveness.
Ethical Oversight & Data Governance: Observational registry analyses synthesize de-identified clinical records adhering strictly to HIPAA Safe Harbor de-identification standards (45 CFR § 164.514(b)) and satisfy criteria for secondary research exemption under HHS Common Rule 45 CFR § 46.104(d)(4). No patient health identifiers are stored or disclosed.
What does real-world evidence show regarding cannabinoids for Metabolic Balance & Incretin Interplay?
As incretin therapies (semaglutide, tirzepatide) proliferate, clinical registry tracking indicates that low-dose, non-intoxicating cannabinoids offer profound nausea mitigation and visceral calming without triggering compensatory appetite escalation when titrated under physician oversight.
What is the clinical scale and data provenance of this Metabolic Balance & Incretin Interplay analysis?
This analysis synthesizes real-world clinical observations from Dr. Benjamin Caplan, MD, who has overseen more than 350,000 patient evaluations across his career (including supervising 250,000+ patients as former Chief Medical Officer of Canna Care Docs). The specific dataset reflects 81,008 outpatient cohorts and 130,447 structured clinical visits tracked in the CED Clinic Clinical Registry.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
“As incretin therapies (semaglutide, tirzepatide) proliferate, clinical registry tracking indicates that low-dose, non-intoxicating cannabinoids offer profound nausea mitigation and visceral calming without triggering compensatory appetite escalation when titrated under physician oversight.”